

Matt T. Wiltermuth

PARTNER

Technology
Transactions
Palo Alto

mwiltermuth@wsgr.com
650-849-3084



FOCUS AREAS

Biotech
Global Generics
Life Sciences
Technology Transactions

HIGHLIGHTS

- **Strategic Commercial and IP Transactions**
Matt represents clients in collaboration, technology acquisition, licensing, mergers and acquisitions, research and development, manufacturing, and distribution arrangements.
- **A Focus on Scientific Clients**
Matt's clients are primarily pharmaceutical, biotechnology, medical device, and life sciences companies.

EXPERIENCE

Matt Wiltermuth is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. His practice focuses on representing clients in strategic commercial and intellectual property transactions, including collaboration, technology acquisition, licensing, mergers and acquisitions, research and development, manufacturing, and distribution arrangements, primarily in the pharmaceutical, biotechnology, medical device, and life sciences industries.

Before attending law school, Matt was a chemical engineer at 3M Company, conducting product and process development.

CREDENTIALS

Education

- J.D., New York University School of Law, 2009
Cum Laude
- B.S., Chemical Engineering, University of Minnesota, 2001
Summa Cum Laude

Admissions

- State Bar of California

MATTERS

Representative Matters

Matt has represented clients in connection with the below matters:

- Alector in its collaboration with GSK

- Arcellx in its collaboration with Kite
- Caribou Biosciences in its cross-license with DuPont
- Cephea Valve Technologies in its collaboration with and acquisition by Abbott
- Kallyope in its collaborations with Novo Nordisk and Sosei Heptares
- Mammoth Biosciences in its collaborations with Bayer, Vertex, and Horizon Discovery Group
- Mesoblast in its collaboration with Grünenthal
- Nanjing Legend Biotech in its collaboration with Janssen
- Peloton Therapeutics in its collaboration with Merck
- Taiho Pharmaceutical Co. Ltd. in its acquisition of Cullinan Pearl and collaboration with Cullinan Oncology
- Tenaya Therapeutics in its initial public offering
- Verily Life Sciences in its collaborations with Procter & Gamble and Sanofi
- Vividion Therapeutics in its collaboration with Roche